MedTrace Logo

Citrate Pharmacokinetics in Critically Ill Liver Failure Patients Receiving CRRT

NCT04959110 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 20

Last updated 2022-11-14

No results posted yet for this study

Summary

Citrate has been proposed as anticoagulation of choice in continuous renal replacement therapy (CRRT). However, little is known about the pharmacokinetics (PKs) and metabolism of citrate in liver failure patients who require CRRT with regional citrate anticoagulation (RCA).

Conditions

  • Citrate Toxicity
  • Regional Citrate Anticoagulation
  • Liver Failure, Acute
  • Liver Failure, Acute on Chronic
  • Pharmacokinetic
  • Continuous Renal Replacement Therapy

Interventions

DIAGNOSTIC_TEST

Pharmacokinetic study

* Start CVVH session with isotonic citrate solution (13.3 mmol/L) as predilution, targeting citrate dose at 3 mmol/L * Blood samples collection at pre-filter for citrate concentration, blood gas, electrolyte and ionized calcium and magnesium * In addition, 10 minutes after the end of citrate infusion, blood samples were taken simultaneously from both pre-filter and post-filter to calculate citrate clearance by filter

Sponsors & Collaborators

  • Chulalongkorn University

    lead OTHER

Study Design

Allocation
NON_RANDOMIZED
Purpose
DIAGNOSTIC
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2019-07-01
Primary Completion
2021-12-31
Completion
2021-12-31

Countries

  • Thailand

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04959110 on ClinicalTrials.gov